+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

CSF monoamine metabolites in schizophrenic patients



CSF monoamine metabolites in schizophrenic patients



Acta Psychiatrica Scandinavica 66(5): 350-360



The monoamine metabolites 3-methoxy-4-hydroxyphenyglycol (MHPG), homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) were measured in the cerebrospinal fluid (CSF) of 16 psychiatrically health controls and in 28 schizophrenic patients. There was no difference in CSF MHPG and HVA levels between the group of patients and the controls. CSF levels of 5-HIAA were significantly lower in schizophrenic patients than in controls. Differential analysis of patients with and without neuroleptics revealed that these findings were not due to drug treatment. Positive correlations were found between the level of 5-HIAA and the items: hallucinatory behaviour, grandiosity, and tension as rated on the Brief Psychiatric Rating Scale. As 5-HIAA CSF data are controversial for nosological entities, the search for correlations between 5-HIAA and individual psychopathological variables could provide more specific indices for psychiatric diagnosis, treatment or prophylaxis.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 042429328

Download citation: RISBibTeXText

PMID: 6184954


Related references

CSF monoamine metabolites in chronic schizophrenic patients who attempt suicide. Psychological Medicine 15(2): 335-340, 1985

Changes in the CSF levels of monoamine metabolites in 102 chronic schizophrenic patients following probenecid before and after neuroleptic medication. Zhonghua Shen Jing Jing Shen Ke Za Zhi 17(5): 273-277, 1984

Monoamine metabolites and amino acids in serum from schizophrenic patients before and during sulpiride treatment. Psychopharmacology 99(3): 322-327, 1989

P-4-47 Effects of clozapine on plasma monoamine metabolites in treatment-refractory schizophrenic patients. European Neuropsychopharmacology 5(3): 341-342, 1995

Neuropsychological test performance, brain morphological measures and CSF monoamine metabolites in schizophrenic patients. Acta Psychiatrica Scandinavica 74(3): 292-301, 1986

Decreased spinal fluid monoamine metabolites and norepinephrine in schizophrenic patients with brain atrophy. Beckmann, H And P Riederer (Ed ) Pathochemical Markers in Major Psychoses; Symposium, Vienna, Austria, July 1983 X+158p Springer-Verlag: New York, N Y , Usa; Berlin, West Germany Illus 88-95, 1985

CSF levels of receptor-active endorphins in schizophrenic patients: correlations with symptomatology and monoamine metabolites. Psychiatry Research 19(2): 93-100, 1986

Cerebroventricular size and cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy volunteers. Psychiatry Research 9(4): 301-308, 1983

Catechol O-methyltransferase and monoamine oxidase A genotypes, and plasma catecholamine metabolites in bipolar and schizophrenic patients. Neurochemistry International 56(6-7): 774-779, 2010

Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients. Psychopharmacology 101(3): 324-331, 1990

Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. British Journal of Psychiatry 147: 276-282, 1985

Cerebrospinal fluid monoamine metabolites and cyclic nucleotides in chronic schizophrenic patients with tardive dyskinesia or drug-induced tremor. Biological Psychiatry 14(3): 509-523, 1979

Schizophrenic behavior and urinary tryptophan metabolites associated with cysteine given with and without a monoamine oxidase inhibitor (tranylcypromine). LIFE SCI 6(5pt 1): 551-560, 1967

Biochemical correlates of behavior in schizophrenic patients. Schizophrenic patients receiving tryptophan and methionine or methionine together with a monoamine oxidase inhibitor. Archives of General Psychiatry 13(6): 521-531, 1965

Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section 5(3): 193-202, 1993